737 related articles for article (PubMed ID: 17643111)
1. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
Kaida D; Motoyoshi H; Tashiro E; Nojima T; Hagiwara M; Ishigami K; Watanabe H; Kitahara T; Yoshida T; Nakajima H; Tani T; Horinouchi S; Yoshida M
Nat Chem Biol; 2007 Sep; 3(9):576-83. PubMed ID: 17643111
[TBL] [Abstract][Full Text] [Related]
2. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.
Corrionero A; Miñana B; Valcárcel J
Genes Dev; 2011 Mar; 25(5):445-59. PubMed ID: 21363963
[TBL] [Abstract][Full Text] [Related]
3. Spliceostatin A interaction with SF3B limits U1 snRNP availability and causes premature cleavage and polyadenylation.
Yoshimoto R; Chhipi-Shrestha JK; Schneider-Poetsch T; Furuno M; Burroughs AM; Noma S; Suzuki H; Hayashizaki Y; Mayeda A; Nakagawa S; Kaida D; Iwasaki S; Yoshida M
Cell Chem Biol; 2021 Sep; 28(9):1356-1365.e4. PubMed ID: 33784500
[TBL] [Abstract][Full Text] [Related]
4. Global analysis of pre-mRNA subcellular localization following splicing inhibition by spliceostatin A.
Yoshimoto R; Kaida D; Furuno M; Burroughs AM; Noma S; Suzuki H; Kawamura Y; Hayashizaki Y; Mayeda A; Yoshida M
RNA; 2017 Jan; 23(1):47-57. PubMed ID: 27754875
[TBL] [Abstract][Full Text] [Related]
5. Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation.
Roybal GA; Jurica MS
Nucleic Acids Res; 2010 Oct; 38(19):6664-72. PubMed ID: 20529876
[TBL] [Abstract][Full Text] [Related]
6. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.
Matsushita K; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Levens D; He L; Liu J; Yoshida M; Nomura F
Mol Cancer Res; 2013 Jul; 11(7):689-98. PubMed ID: 23594796
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of the spliceosome subunit SF3b triggers exon junction complex-independent nonsense-mediated decay.
Carvalho T; Martins S; Rino J; Marinho S; Carmo-Fonseca M
J Cell Sci; 2017 May; 130(9):1519-1531. PubMed ID: 28302904
[TBL] [Abstract][Full Text] [Related]
8. A U2-snRNP-independent role of SF3b in promoting mRNA export.
Wang K; Yin C; Du X; Chen S; Wang J; Zhang L; Wang L; Yu Y; Chi B; Shi M; Wang C; Reed R; Zhou Y; Huang J; Cheng H
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7837-7846. PubMed ID: 30923118
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of splicing and nuclear retention of pre-mRNA by spliceostatin A in fission yeast.
Lo CW; Kaida D; Nishimura S; Matsuyama A; Yashiroda Y; Taoka H; Ishigami K; Watanabe H; Nakajima H; Tani T; Horinouchi S; Yoshida M
Biochem Biophys Res Commun; 2007 Dec; 364(3):573-7. PubMed ID: 17961508
[TBL] [Abstract][Full Text] [Related]
10. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
[TBL] [Abstract][Full Text] [Related]
11. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product.
Hasegawa M; Miura T; Kuzuya K; Inoue A; Won Ki S; Horinouchi S; Yoshida T; Kunoh T; Koseki K; Mino K; Sasaki R; Yoshida M; Mizukami T
ACS Chem Biol; 2011 Mar; 6(3):229-33. PubMed ID: 21138297
[TBL] [Abstract][Full Text] [Related]
12. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
13. Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing.
Gamboa Lopez A; Allu SR; Mendez P; Chandrashekar Reddy G; Maul-Newby HM; Ghosh AK; Jurica MS
ACS Chem Biol; 2021 Mar; 16(3):520-528. PubMed ID: 33617218
[TBL] [Abstract][Full Text] [Related]
14. Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line.
Arai K; Buonamici S; Chan B; Corson L; Endo A; Gerard B; Hao MH; Karr C; Kira K; Lee L; Liu X; Lowe JT; Luo T; Marcaurelle LA; Mizui Y; Nevalainen M; O'Shea MW; Park ES; Perino SA; Prajapati S; Shan M; Smith PG; Tivitmahaisoon P; Wang JY; Warmuth M; Wu KM; Yu L; Zhang H; Zheng GZ; Keaney GF
Org Lett; 2014 Nov; 16(21):5560-3. PubMed ID: 25376106
[TBL] [Abstract][Full Text] [Related]
15. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.
Larrayoz M; Blakemore SJ; Dobson RC; Blunt MD; Rose-Zerilli MJ; Walewska R; Duncombe A; Oscier D; Koide K; Forconi F; Packham G; Yoshida M; Cragg MS; Strefford JC; Steele AJ
Leukemia; 2016 Feb; 30(2):351-60. PubMed ID: 26488112
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and NMR analyses of an SF3b155-p14-U2AF-RNA interaction network involved in branch point definition during pre-mRNA splicing.
Spadaccini R; Reidt U; Dybkov O; Will C; Frank R; Stier G; Corsini L; Wahl MC; Lührmann R; Sattler M
RNA; 2006 Mar; 12(3):410-25. PubMed ID: 16495236
[TBL] [Abstract][Full Text] [Related]
17. RQN-18690A (18-deoxyherboxidiene) targets SF3b, a spliceosome component, and inhibits angiogenesis.
Kakeya H; Kaida D; Sekiya H; Nagai K; Yoshida M; Osada H
J Antibiot (Tokyo); 2016 Feb; 69(2):121-3. PubMed ID: 26350783
[No Abstract] [Full Text] [Related]
18. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.
Folco EG; Coil KE; Reed R
Genes Dev; 2011 Mar; 25(5):440-4. PubMed ID: 21363962
[TBL] [Abstract][Full Text] [Related]
19. U2 snRNP is required for expression of the 3' end of genes.
Koga M; Satoh T; Takasaki I; Kawamura Y; Yoshida M; Kaida D
PLoS One; 2014; 9(5):e98015. PubMed ID: 24845214
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464.
Osman S; Albert BJ; Wang Y; Li M; Czaicki NL; Koide K
Chemistry; 2011 Jan; 17(3):895-904. PubMed ID: 21226105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
